{"title":"Potential Application of a Water-Soluble Fullerene C60 Decorated with Diethylene Glycol in Treatment of Osteoarthritis","authors":"Rui He, Alyssa Costello, Yanjie Liu, Weicheng Wang, Zhichang Zhang, Quanjun Cui, Xinlin Yang","doi":"10.1002/anbr.202500020","DOIUrl":null,"url":null,"abstract":"<p>Inflammatory macrophages play a role in cartilage degeneration associated with osteoarthritis (OA) via signaling cascades that result in production of inflammatory substances. This study aims to characterize compound F2, C<sub>60</sub>(NCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OH)<sub>5</sub>, a newly synthesized ethoxyethanol derivative of iminofullerene, and its potential to reduce inflammatory macrophage activity. First, compound F2 is synthesized and labeled with <sup>99m</sup>Tc to create <sup>99m</sup>Tc-F2. It is then added to lipopolysaccharide (LPS)-exposed bone marrow macrophages (BMMs) to determine its effect on macrophage activation, nitric oxide production, and expression of inflammatory markers iNOS, IL-6, Fpr2, and TLR4. An animal model of osteoarthritis is also injected with <sup>99m</sup>Tc-F2 to visualize its localization in vivo. This study demonstrates successful synthesis and radiolabeling of the compound F2 molecule. It also demonstrates that compound F2 reduces nitrite production and suppresses the expression of TNF α, IL-6, iNOS, Fpr2, and TLR4 in BMMs exposed to LPS. Additionally, in rats with surgically transected anterior cruciate ligaments, intravenous administration of radioisotope-labeled compound F2 exhibits selective enrichment in the injured knee. These findings suggest that compound F2 mitigates macrophage activation, decreases inflammatory marker expression, and is located to damaged areas, highlighting its potential as a therapeutic option for OA management.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 9","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500020","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/anbr.202500020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Inflammatory macrophages play a role in cartilage degeneration associated with osteoarthritis (OA) via signaling cascades that result in production of inflammatory substances. This study aims to characterize compound F2, C60(NCH2CH2OCH2CH2OH)5, a newly synthesized ethoxyethanol derivative of iminofullerene, and its potential to reduce inflammatory macrophage activity. First, compound F2 is synthesized and labeled with 99mTc to create 99mTc-F2. It is then added to lipopolysaccharide (LPS)-exposed bone marrow macrophages (BMMs) to determine its effect on macrophage activation, nitric oxide production, and expression of inflammatory markers iNOS, IL-6, Fpr2, and TLR4. An animal model of osteoarthritis is also injected with 99mTc-F2 to visualize its localization in vivo. This study demonstrates successful synthesis and radiolabeling of the compound F2 molecule. It also demonstrates that compound F2 reduces nitrite production and suppresses the expression of TNF α, IL-6, iNOS, Fpr2, and TLR4 in BMMs exposed to LPS. Additionally, in rats with surgically transected anterior cruciate ligaments, intravenous administration of radioisotope-labeled compound F2 exhibits selective enrichment in the injured knee. These findings suggest that compound F2 mitigates macrophage activation, decreases inflammatory marker expression, and is located to damaged areas, highlighting its potential as a therapeutic option for OA management.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
